{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:31:09Z","timestamp":1780572669255,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T00:00:00Z","timestamp":1410912000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00296-014-3133-9","type":"journal-article","created":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T18:01:48Z","timestamp":1410976908000},"page":"661-668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis"],"prefix":"10.1007","volume":"35","author":[{"given":"Asha","family":"Krishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick J.","family":"Stobaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parakkal","family":"Deepak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,17]]},"reference":[{"key":"3133_CR1","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/gast.2002.33426","volume":"122","author":"WJ Sandborn","year":"2002","unstructured":"Sandborn WJ, Targan SR (2002) Biologic therapy of inflammatory bowel disease. Gastroenterology 122:1592\u20131608","journal-title":"Gastroenterology"},{"key":"3133_CR2","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra032906","volume":"350","author":"NJ Olsen","year":"2004","unstructured":"Olsen NJ, Stein CM (2004) New drugs for rheumatoid arthritis. N Engl J Med 350:2167\u20132179","journal-title":"N Engl J Med"},{"key":"3133_CR3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2036.2005.02564.x","volume":"22","author":"LA Garc\u00eda Rodr\u00edguez","year":"2005","unstructured":"Garc\u00eda Rodr\u00edguez LA, Gonz\u00e1lez-P\u00e9rez A, Johansson S, Wallander MA (2005) Risk factors for inflammatory bowel disease in the general population. Aliment Pharmacol Ther 22:309\u2013315","journal-title":"Aliment Pharmacol Ther"},{"key":"3133_CR4","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.semarthrit.2008.06.004","volume":"39","author":"B Haraoui","year":"2009","unstructured":"Haraoui B, Krelenbaum M (2009) Emergence of Crohn\u2019s disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin Arthritis Rheum 39:176\u2013181","journal-title":"Semin Arthritis Rheum"},{"key":"3133_CR5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00296-009-0991-7","volume":"30","author":"V Wiegering","year":"2010","unstructured":"Wiegering V, Morbach H, Dick A, Girschick HJ (2010) Crohn\u2019s disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature. Rheumatol Int 30:801\u2013804","journal-title":"Rheumatol Int"},{"key":"3133_CR6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005176-200408000-00016","volume":"39","author":"FM Ruemmele","year":"2004","unstructured":"Ruemmele FM, Prieur AM, Talbotec C, Goulet O, Schmitz J (2004) Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis. J Pediatr Gastroenterol Nutr 39:203\u2013206","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"3133_CR7","first-page":"752","volume":"32","author":"J Oh","year":"2005","unstructured":"Oh J, Arkfeld DG, Horwitz DA (2005) Development of Crohn\u2019s disease in a patient taking etanercept. J Rheumatol 32:752\u2013753","journal-title":"J Rheumatol"},{"key":"3133_CR8","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3899\/jrheum.100809","volume":"38","author":"TD Dijken van","year":"2011","unstructured":"van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H et al (2011) Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 38:1441\u20131446","journal-title":"J Rheumatol"},{"key":"3133_CR9","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/rheumatology\/keq136","volume":"49","author":"A Dallocchio","year":"2010","unstructured":"Dallocchio A, Canioni D, Ruemmele F, Duquesne A, Scoazec JY, Bouvier R et al (2010) Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology (Oxford) 49:1694\u20131698","journal-title":"Rheumatology (Oxford)"},{"key":"3133_CR10","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1111\/j.1572-0241.2000.02262.x","volume":"95","author":"JB Felder","year":"2000","unstructured":"Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G (2000) Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 95:1949\u20131954","journal-title":"Am J Gastroenterol"},{"key":"3133_CR11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jbspin.2011.10.001","volume":"79","author":"\u00c9 Toussirot","year":"2012","unstructured":"Toussirot \u00c9, Houvenagel \u00c9, Go\u00ebb V, Fouache D, Martin A, Le Dantec P et al (2012) Development of inflammatory bowel disease during anti-TNF-\u03b1 therapy for inflammatory rheumatic disease. A nationwide series. Joint Bone Spine 79:457\u2013463","journal-title":"Joint Bone Spine"},{"key":"3133_CR12","unstructured":"The Adverse Event Reporting System (AERS) Older quarterly data files [homepage on the Internet]. U.S. Food and Drug Administration [updated 2013 Aug 15; cited 2014 June 20]. http:\/\/www.fda.gov\/"},{"key":"3133_CR13","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/ibd.22990","volume":"19","author":"MF Dubeau","year":"2013","unstructured":"Dubeau MF, Iacucci M, Beck PL, Moran GW, Kaplan GG, Ghosh S et al (2013) Drug-induced inflammatory bowel disease and IBD-like conditions. Inflamm Bowel Dis 19:445\u2013456","journal-title":"Inflamm Bowel Dis"},{"key":"3133_CR14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2005.06.021","volume":"129","author":"CN Bernstein","year":"2005","unstructured":"Bernstein CN, Wajda A, Blanchard JF (2005) The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 129:827\u2013836","journal-title":"Gastroenterology"},{"key":"3133_CR15","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/ajg.2009.81","volume":"104","author":"C Ha","year":"2009","unstructured":"Ha C, Magowan S, Accortt NA, Chen J, Stone CD (2009) Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol 104:1445\u20131451","journal-title":"Am J Gastroenterol"},{"key":"3133_CR16","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/archdischild-2011-300633","volume":"96","author":"MD Kappelman","year":"2011","unstructured":"Kappelman MD, Galanko JA, Porter CQ, Sandler RS (2011) Association of paediatric inflammatory bowel disease with other immune-mediated diseases. Arch Dis Child 96:1042\u20131046","journal-title":"Arch Dis Child"},{"key":"3133_CR17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1529-8019.2010.01304.x","volume":"23","author":"L Naldi","year":"2010","unstructured":"Naldi L, Mercuri SR (2010) Epidemiology of comorbidities in psoriasis. Dermatol Ther 23:114\u2013118","journal-title":"Dermatol Ther"},{"key":"3133_CR18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239\u2013245","journal-title":"Clin Pharmacol Ther"},{"key":"3133_CR19","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/apt.12385","volume":"38","author":"P Deepak","year":"2013","unstructured":"Deepak P, Stobaugh DJ, Sherid M, Sifuentes H, Ehrenpreis ED (2013) Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System. Aliment Pharmacol Ther 38:388\u2013396","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"3133_CR20","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","volume":"121","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD et al (2001) Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121(5):1088\u20131094","journal-title":"Gastroenterology"},{"issue":"7","key":"3133_CR21","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","volume":"124","author":"JM Brande Van den","year":"2003","unstructured":"Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I et al (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn\u2019s disease. Gastroenterology 124(7):1774\u20131785","journal-title":"Gastroenterology"},{"issue":"3","key":"3133_CR22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-2036.2005.02309.x","volume":"21","author":"C Shen","year":"2005","unstructured":"Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P et al (2005) Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21(3):251\u2013258","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"3133_CR23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/ard.60.2.133","volume":"60","author":"L Berg","year":"2001","unstructured":"Berg L, Lampa J, Rogberg S, van Vollenhoven R, Klareskog L (2001) Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann Rheum Dis 60(2):133\u2013139","journal-title":"Ann Rheum Dis"},{"key":"3133_CR24","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/gut.2009.199679","volume":"60","author":"CW Lees","year":"2011","unstructured":"Lees CW, Barrett JC, Parkes M, Satsangi J (2011) New IBD genetics: common pathways with other diseases. Gut 60:1739\u20131753","journal-title":"Gut"},{"key":"3133_CR25","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s00125-009-1491-8","volume":"52","author":"EA Gale","year":"2009","unstructured":"Gale EA (2009) Collateral damage: the conundrum of drug safety. Diabetologia 52:1975\u20131982","journal-title":"Diabetologia"},{"key":"3133_CR26","unstructured":"FDA Adverse Event Reporting System (FAERS) (formerly AERS) [homepage on the Internet]. U.S. Food and Drug Administration [updated 2012 Sep 10; cited 2014 June 20]. http:\/\/www.fda.gov\/"},{"key":"3133_CR27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0889-857X(03)00043-7","volume":"29","author":"W Holden","year":"2003","unstructured":"Holden W, Orchard T, Wordsworth P (2003) Enteropathic arthritis. Rheum Dis Clin North Am 29:513\u2013530","journal-title":"Rheum Dis Clin North Am"},{"key":"3133_CR28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/art.1780370105","volume":"37","author":"M Leirisalo-Repo","year":"1994","unstructured":"Leirisalo-Repo M, Turunen U, Stenman S, Helenius P, Sepp\u00e4l\u00e4 K (1994) High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 37:23\u201331","journal-title":"Arthritis Rheum"},{"key":"3133_CR29","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.berh.2008.09.008","volume":"22","author":"M Ramos-Casals","year":"2008","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Soto MJ, Cuadrado MJ, Khamashta MA (2008) Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22:847\u2013861","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-014-3133-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-014-3133-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-014-3133-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T11:21:56Z","timestamp":1559042516000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-014-3133-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,17]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["3133"],"URL":"https:\/\/doi.org\/10.1007\/s00296-014-3133-9","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,17]]}}}